David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.

Slides:



Advertisements
Similar presentations
Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
Advertisements

Use of Data Monitoring Committees (DMC) in Device Trials: An FDA Division of Cardiovascular Devices (DCD) Perspective Bram Zuckerman MD, FACC
TISSUE BANKING Challenging to Say the Least
Susan Burner Bankowski, M.S., J.D. Chair, OHSU IRB
How To Impact Your Research: An Overview of Research Support Services Quincy J. Byrdsong, Terri Hagan, and Alice Owens-Gatlin Research Services Consultants.
Donald T. Simeon Caribbean Health Research Council
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Legal Framework for Information Sharing in Organ Donation and Transplantation Alexandra K. Glazier, Esq. VP & General Counsel New England Organ Bank.
Recently Issued OHRP Documents: Guidance on Subject Withdrawal and Draft Revised FWA Secretary’s Advisory Committee on Human Research Protections October.
Ad Hoc Disease Transmission Advisory Committee Spring 2015.
DONATION AND TRANSPLANTATION COMMUNITY OF PRACTICE GOAL MESSAGING: 5000 IN FIVE.
What Is Quality by Design?. Quality by Design: QbD Defined Prospectively examining the objectives of a trial and defining factors critical to meeting.
Module 2 Sealy Center on Aging What kinds of scholarly products can I produce?
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Adverse Events, Unanticipated Problems, Protocol Deviations & other Safety Information Which Form 4 to Use?
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Challenges to Research and Innovation to Optimize Deceased Donor Organ Quality and Quantity Peter Abt, MD Sandy Feng, MD PhD American Society of Transplant.
HIV Prevention Trials Network Update Africa Regional Working Group 20 May 2003.
International Research & Research Involving Children K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
Compliance Issues for Medical Research at Healthcare Systems Jerry Castellano, Pharm.D., CIP Corporate Director Institutional Review Board Christiana Care.
Minnesota Alliance for Patient Safety Improving Regulation Discussion Operations Committee January 7, 2014.
ACCORD Mark Roberts ACCORD Business Lead. Achieving Comprehensive Coordination in ORgan Donation EU funded Joint Action Joint Action led and coordinated.
Challenges with conducting NBS pilot studies Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics Chief, Division of Medical Ethics and Humanities Associate.
Organ Donation Past, Present and Future Donor Identification and Referral Rachel Stoddard-Murden Dr Alex Manara 9 th July SOUTH WEST.
Secretary’s Advisory Committee on Human Subjects Protections (SACHRP) Summary of Responses on: Advanced Notice of Proposed Rulemaking (ANPRM) on Holding.
Ethical and Regulatory Considerations in Research using Residual Specimens Jeffrey R. Botkin, M.D., M.P.H. Professor of Pediatrics and Medical Ethics Associate.
Common Rule and FDA Regulation Comparison David Forster Jeff Cooper Gary Chadwick.
Addressing the Requirements Outlined in the HIV Organ Policy Equity Act Organ Procurement Organization Committee Spring 2015.
Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.
OPTN Strategic Plan Maureen McBride United Network for Organ Sharing August 28, 2012.
The Research Subject Advocate (RSA). Pictured, left to right: Andrea Saltzman, RN; Enrico Cagliero, MD; Debi Dunkless.
Conducting Clinical Risk Assessments And Implementing Compliance Practices Jane L. Stratton Chiron Corporation VP/Associate General Counsel Chief Compliance.
The NCI Central IRB Initiative Third Annual Medical Research Summit Washington, D.C. March 2003.
Who we are What we do Where we are going How you can help.
Ethics Review Committee | 28 th -30 th June 2009, Chengdu 1 |1 | The purpose and process of formal ethical review International Workshop of Ethics Review.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
(Slide 1 of 22) Response to the National Vaccine Advisory Committee Recommendations on the Immunization Safety Office Scientific Agenda Frank DeStefano,
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
VCA Donation: legal framework and NEOB experience Alexandra K. Glazier, JD MPH VP & General Counsel New England Organ Bank.
Yadvindera (Bobby) Bains MD Director of Radiation Oncology, Laredo Medical Center Adjunct Associate Professor, Dept of Radiation Oncology, University of.
Proposal to Reduce the Reporting Requirements for the Deceased Donor Registration (DDR) Form Organ Procurement Organization Committee Fall 2014.
Introduction Organ Transplantation Program Update Advisory Committee on Organ Transplantation November 17, 2015 Melissa Greenwald, MD Acting Director Division.
Proposal to Align OPTN Policies with the 2013 PHS Guideline for Reducing Transmission of HIV, HBV, and HCV Through Solid Organ Transplantation Ad Hoc Disease.
David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill.
Ad Hoc Disease Transmission Advisory Committee Fall 2014.
1 Proposal to Modify Pediatric Lung Allocation Policy Thoracic Organ Transplantation Committee Fall 2015.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
VA Central IRB K. Lynn Cates, MD Assistant Chief Research & Development Officer Office of Research & Development Department of Veterans Affairs September.
Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.
0 Ethics Lecture Research. ACADEMY OF OPHTHALMOLOGY Disclosures  The speaker has no financial interest in the subject matter of this.
Institutional Review Board (IRB) for Human Subject Protections: Working with the IRB Erin A McClure, PhD Department of Psychiatry and Behavioral Sciences.
White Paper: Ethical Considerations of Imminent Death Donation
What is a Data and Safety Monitoring Plan and how do I get one?
Organ Procurement Organization Committee Fall 2014
Guidance on Optimizing VCA Recovery from Deceased Donors
Pediatric Transplantation Committee
Organ Procurement Organization Committee Report
Eliminate the Use of Regions in VCA Distribution
Modify HOPE Act Variance to Include Other Organs
OPTN/UNOS Transplant Coordinators Committee
Vascularized Composite Allograft (VCA) Transplantation Committee
OPTN/UNOS Transplant Coordinators Committee
Guidance on Effective Practices in Broader Distribution
Vascularized Composite Allograft Transplantation Committee Fall 2014
Vascularized Composite Allograft (VCA) Transplantation Committee
Vascularized Composite Allograft (VCA) Transplantation Committee
White Paper: Split Versus Whole Liver Transplantation
Vascularized Composite Allograft (VCA) Transplantation Committee
Presentation transcript:

David A. Gerber, MD Professor and Chief Division of Abdominal Transplantation Department of Surgery University of North Carolina at Chapel Hill

Organ Quality Limits Transplant Outcomes  Insufficient ideal donors; increase in DCD, marginal and expanded criteria donors Donor quality defined by post-transplant outcomes according to risk of graft loss (patient death or need for retransplantation)  Inferior organ quality engenders recipient morbidity and mortality

The Need for Innovation and Research in Donor Intervention and Treatment  To increase the number of organs available for transplantation Mitigate waiting list candidate morbidity and mortality  To improve the quality of organs used for transplantation Mitigate recipient morbidity and mortality

Obstacles to Research and Innovation in Deceased (Brain Dead) Donors  Scientific  Ethical  Logistical  Regulatory Investigator Donors / donor families Donor hospitals Organ Procurement Organizations OPTN Waiting list candidates Transplant recipients / centers Constituents:

Problem  Current infrastructure is inadequate to support effective donor intervention and treatment studies. The magnitude and complexity of the challenges require guidelines/processes to facilitate the optimal design and safe execution of clinical trials in deceased donors.

Donor Intervention Research ACOT Work Group: Key Focus Areas  Protocol and Oversight: – Key elements – Sharing  Donor-Focused Issues: – Donor authorization for research – Ethical considerations  Transplant Center/Recipient Issues: – Risk – Consent

Specific Actions to be Considered  Identify existing mechanisms, pathways, etc. and alternative pathways that could facilitate unique donor-related research activities

Donor Intervention Research ACOT Work Group: Key Focus Areas  Protocol and Oversight: – Key elements – Sharing – Possibility of housing an IRB-type entity within the OPTN is under review and consideration  Donor-Focused Issues: – Authorization for research – Ethical considerations  Transplant Center/Recipient Issues: – Risk – Consent

Donor Intervention Research ACOT Work Group  Point of emphasis needs to be on big science with respect to guidance.  This strategy would allow the development of processes that capture all potential donor-related research activities.  Complementary efforts are ongoing with IOM  Recent acknowledgement that there is funding for IOM planning meeting  Timeline for IOM study

Donor Intervention Research ACOT Work Group—Potential Protocol Process Develop Proposal Input: Personal observation; animal studies; literature review Responsibility: Researcher Key Question: Research question examined Develop Study Plan Input: Colleagues; Research Consortium; literature review Responsibility: Researcher Oversight: Researcher organization Key Question: Process and partners? Scientific Merit Review Input: Current or developed requirements Responsibility: Researcher submitted; Committee review Oversight: TBD (where committee is housed) Key Question: Is study worth doing?

Donor Intervention Research ACOT Work Group: Potential Protocol Process (c ont.) Resource RISK: Description of levels of risk to recipient Data and Safety Monitoring Input: Standardized reporting process Responsibility: Research team reporting; Board monitoring and action Oversight: DSMB, OHRP Key Questions: Does study protect subject? Are adverse events identified and mitigated? Human Subjects Review Input: Guidance from OHRP, DIRB requirements Responsibility: Researcher submitted; DIRB review Oversight: DIRB, OHRP Key Question: Does study demonstrate protection of human subjects? Resource DIRB/DSMB: Model elements for DIRB review and DSMB monitoring; centralized versus regional Allocation: Impact of allocation on protocol design and implementation; impact on non-targeted organs

Topics Addressed  Donor-focused issues – Authorization under UAGA – dual purpose of transplant and research – Standards for OPO review and participation – Donor hospital considerations  Transplant-focused issues – Quantifying risk – Communicating info about protocol to accepting team – required elements – Informed consent of recipient or possible waiver of documentation of informed consent

Developing a Recommendation  Points of Focus  Logistical Issues  Oversight/framework  OHRP and request for secretarial waiver for IRB review  Prioritization of donor-related research activities  HHS support system developments that facilitate donor intervention research  Decouple funding from process for research